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A B S T R A C T
The production of broadly neutralizing antibodies (bNAbs) is a major goal in the development of an HIV-1
vaccine. The membrane-proximal external region (MPER) of gp41, which plays a critical role in the virus
membrane fusion process, is highly conserved and targeted by bNAbs 2F5, 4E10, and 10E8. As such, MPER could
be a promising epitope for vaccine design. In this study, diphtheria toxin domain A (CRM197, amino acids
1–191) was used as a scaffold to display the 2F5 and 4E10 epitopes of MPER, named CRM197-A-2F5 and
CRM197-A-4E10. Modest neutralizing activities were detected against HIV-1 clade B and D viruses in the sera
from mice immunized with CRM197-A-4E10. Monoclonal antibodies raised from CRM197-A-4E10 could neu-
tralize several HIV-1 strains, and epitope-mapping analysis indicated that some antibodies recognized the same
amino acids as 4E10. Collectively, we show that 4E10-like antibodies can be induced by displaying MPER
epitopes using an appropriate scaffold. These results provide insights for HIV-1MPER-based immunogens design.
1. Introduction
Human immunodeficiency virus type 1 (HIV-1) is still an epidemic
around the world despite a significant reduction in rates of infection
and death by effective antiretroviral therapy (ART). Developing a
protective HIV-1 vaccine is an ideal way to prevent HIV-1 infection and
control HIV-1 transmission. The HIV-1 envelope (Env) glycoprotein, a
precursor gp160 protein of gp120 and gp41, is the sole antigen exposed
on the virus surface and plays an essential role in the virus replication
cycle by mediating fusion between the viral and cellular membranes
[1]. With the application of novel technologies, such as single B cell
sorting, deep sequencing, and microneutralization assays, there are now
dozens of broadly neutralizing antibodies (bNAbs) isolated from HIV-
1–infected patients that can target the Env protein [2–4]. All of these
bNAbs map to six major antigenic sites on Env: the CD4 binding site
[5–7], the V1/V2 loop [8,9], the V3 loop with Asn332 glycan patch
[10,11] the gp120/gp41 interface [12], the gp41 fusion peptide region
[13,14] and the membrane-proximal external region (MPER) [15–17].
Among the vulnerable sites on Env, the MPER epitope is highly
conserved and has a tryptophan-rich, linear epitope that is recognized
by bNAbs including 2F5, Z13e1, 4E10, m66 and 10E8 [18]. Structural
analysis shows that these bNAbs target the fusion-intermediate con-
formation, and prevent membrane fusion by interfering with the for-
mation of the six-helix bundle consisting of antiparallel coiled coils
formed by the N-terminal and C-terminal heptad repeats of gp41
[19,20]. Although numerous immunization studies have focused on the
MPER, bNAbs have not yet to be successfully elicited by MPER im-
munogens. This is likely due to the poor immunogenicity of MPER and
the structural shield when MPER interacting with membrane [21].
Several different approaches have been employed to address the
challenges associated with MPER immunogenicity: some authors have
used liposomes and scaffolds to present the MPER epitope, whereas
others have created chimeras of MPER and virus-like particles for ex-
pression [22–26]. The Diphtheria toxin (DT) is a protein vector fre-
quently used for expression studies. In particular, the mutant form,
CRM197, which harbors an inactivating Gly52Glu mutation, is often
used as an intramolecular adjuvant to enhance the immunogenicity of
polysaccharides, haptens, Meningitec and Menveo for meningitis
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[27–31]. DT has three domains: a receptor-binding domain R (aa
385–535), a transmembrane domain T (aa 201–384) and a catalytic
domain A (aa 1–191) otherwise referred to as CRM197-A [32,33].
Wang and colleagues reported that higher neutralization titers can be
achieved by fusing the human papillomavirus (HPV) major capsid
protein L2 peptide with CRM197-A as opposed to CRM197 or CRM389
(aa 1–389) [34]. The other instance is the truncated HEV capsid protein
(E2) fused to CRM197-A showed 10-times higher immunogenicity than
that of particulate p239 in mice and conferred comparable Hepatitis E
protection as Hecolin in non-human primates [35]. Taken together,
CRM197 has been corroborated as immunogenicity enhancer through
either chemical covalent coupling to polysaccharide in full-length form
or fusion expression using its A domain.
In this study, we sought to design an improved method for the
production of MPER bNAbs. We fused MPER epitopes (specifically, the
2F5 and 4E10 epitopes) separately to the C-terminus of CRM197-A
using a GGGGSGGGGSGGGGS linker. The recombinant CRM197-A-2F5
and CRM197-A-4E10 proteins were expressed in Escherichia coli and
then tested in immunogenicity assays in mice. The results show a
broader and more potent neutralizing activity of immune sera from the
CRM197-A-4E10 group compared with the CRM197-A-2F5 group. We
screened monoclonal antibodies from mice injected with CRM197-A-
4E10, and acquired 5 antibodies with 4E10-like properties that re-
cognized the same key amino acids as 4E10 and showed cross-neu-
tralization against HIV-1 strains. Overall, these results provide im-
portant insight for MPER-based HIV-1 vaccine design and offer
evidence for the promising role of MPER in the production of HIV-1
immunogenic determinants.
2. Materials and methods
2.1. Construction, expression and purification of epitope fusion proteins
The 2F5 (ELLELDKWA) and 4E10 (LWNWFDITNWL) epitopes were
linked to the CRM197-A C-terminus by a GGGGSGGGGSGGGGS linker
and cloned into the pTO-T7 vector. Plasmids were then transformed
into E. coli BL21 competent cells and cultured overnight at 37 °C in
solid LB medium containing kanamycin. The single bacterial colonies
were inoculated in liquid LB medium containing antibiotics, and cul-
tures were grown to an OD600 of 0.8. Fusion proteins (respectively
designated CRM197-A-2F5 and CRM197-A-4E10) were induced with
1mM isopropyl-β-D-thiogalactopyranoside (IPTG) at 25 °C for 12 h.
Bacterial cell pellets were harvested by centrifugation at 7000 ×g for
10min in a Beckman Avanti J-26 s centrifuge. Cell pellets were re-
suspended with lysis buffer (5 mM Tris-HCl, 1 mM EDTA, 300mM
NaCl), sonicated (SONICS VCX800), and then centrifuged at 25,000 ×g
for 10min at 20 °C. The fusion proteins were then purified by washing
the inclusion bodies thrice each in buffer with and then without 0.5%
Triton X-100. Proteins were solubilized in 20mM Tris-HCl pH 8.0 with
8M urea, and insoluble debris was removed by centrifugation for
10min at 25,000 ×g. The supernatant was dialyzed into 20mM TB8.0
over a gradient containing 6M, 4M, 2M, 1M, and no urea, and then
Fig. 1. Construction and characterization of
CRM197-A-2F5 and CRM197-A-4E10 fusion
proteins. (A) The MPER conservative analysis
by WebLogo, in which 1000 Env sequences
from HIV sequence database website http://
www.hiv.lanl.gov/ were used. The epitope
targeted by 2F5 and 4E10 is indicated. (B)
Schematic diagrams of the CRM197-A-2F5 and
CRM197-A-4E10 fusion proteins. The epitopes
targeted by 2F5 and 4E10 were respectively
linked to the CRM197-A C-terminus with a 15-
aa long flexible linker (GGGGSGGGGSGGGGS).
(C) SDS-PAGE and western blotting analysis of
the purified CRM197-A-2F5 and CRM197-A-
4E10 fusion proteins. The 2F5 and 4E10 mAbs
were used as the detecting antibodies. Protein
CRM197-A served as the negative control. (D)
Antigenicity of the CRM197-A-2F5 and
CRM197-A-4E10 fusion proteins by ELISA. The
CRM197-A-2F5 and CRM197-A-4E10 fusion
proteins were coated into 96-microwell plates
and reacted to mAb 2F5 and 4E10, respec-
tively.
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centrifugated at 25,000 ×g for 10min, as described elsewhere [36].
The supernatant proteins were analyzed by SDS-PAGE and im-
munoblotting with 2F5 and 4E10 antibodies (obtained from Immune
Tech, New York, USA). The purified proteins were stored at −80 °C
before further use.
2.2. Enzyme-linked immunosorbent assays (ELISA)
For ELISA assays, proteins were solubilized in carbonate buffer (pH
9.6), and coated into the wells of a 96-well microtiter plate at 37 °C for
2 h. Plates were washed once with PBST and then blocked with buffer
(0.5% casein, 2% gelatin, 0.1% preservative (proclin-300) in PBS)
overnight at 4 °C. Samples were 3-fold serially diluted with sample
buffer (2% BSA in PBS with 0.05% Tween-20) and then added in tri-
plicate into the wells of a 96-well plate for 1 h at 37 °C. The horseradish
peroxidase (HRP)-conjugated goat anti-human or anti-mouse secondary
antibody (1:5000 dilution) (Abcam, Cambridge, UK) was used for de-
tection antibody and incubated for 30min at 37 °C. The OD at 450/
630 nm was measured using a microplate reader (Antu Experimental
Company, Beijing, China).
2.3. Ethics Statement and Mice Immunization
Animal experiments were approved by the Xiamen University
Laboratory Animal Center (Approval number: XMULAC20160051; ap-
proval date: 07/03/2016). All procedures were conducted in ac-
cordance with animal ethics guidelines and approved protocols.
Female, 8-week-old BALB/c mice were purchased from Shanghai Slack
Laboratory Animals Enterprise Co., Ltd. Three groups of mice (n=5
per group) were respectively immunized subcutaneously with PBS
(control), CRM197-A-2F5 protein, or CRM197-A-4E10 protein. Mice
were primed with 200 μg protein mixed with Freund’s complete
Fig. 2. Immunogenicity assay in mice for CRM197-A-2F5 and CRM197-A-4E10 fusion proteins. Serum taken at 8 weeks after the first immunization were analyzed by
ELISA. (A) CRM197-A-2F5 and CRM197-A-4E10 fusion proteins were used as coating antigens. (B) gp41 extracellular domain protein produced by HEK293FT cells
was used as coating antigen. Sera were diluted 100-fold. Pre-immune serum were used as a negative control. (C) Neutralizing activity of the immune serum against
four HIV-1 viruses: HIVNL4-3 (clade B), HIV89.6 (clade B), HIVMJ4 (clade C) and HIV94UG114 (clade D) in the TZM-b1 assay. The results represent three independent
experiments.
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adjuvant, and then subsequently immunized with 100 μg protein with
Freund’s incomplete adjuvant. The immunization schedule comprised
four doses at 2-week intervals. Serum samples were collected, in-
activated at 56 °C for 30min, and stored at −20 °C for ELISA and
neutralization assays.
2.4. HIV-1 neutralization assay
The infectious molecular clone pNL4-3, p89.6, pMJ4 and p94UG114
were obtained from the National Institutes of Health (NIH) AIDS
Research and Reference Program. HIV-1 virus production and titration
were performed with TZM-b1 cells to determine the neutralizing ac-
tivity, as previously described [37]. In brief, 293FT cells were trans-
fected with the infectious molecular clone plasmids using Lipofecta-
mine 2000 (Invitrogen; Carlsbad, CA). At 12 h post-transfection, the
culture medium was replaced with fresh medium and HIV-1 virus su-
pernatant was harvested 36 h later. The virus was titrated onto TZM-b1
cells [38,39]. The neutralization assay was performed, as follows: In-
activated serum samples or antibodies were 3-fold serially diluted (1:20
to 1:4860) in complete Dulbecco’s modified eagle medium (DMEM).
Virus (50 μL; at 100 TCID50), 15 μg/mL DEAE, and serum or antibodies
were mixed and incubated at 37 °C for 1 h, and then added to 100 μL of
prepared cells (1× 104 cells/well) in 96-well plates. Cells were further
incubated at 37 °C with 5% CO2 for 48 h, and then fixed with 0.2%
glutaraldehyde and 1% formaldehyde, and stained with X-gal substrate
[37]. The HIV-infected cell spots were counted using an Immunospot
Series Analyzer (Cellular Technology, Cleveland, OH). The half-max-
imal inhibitory dilutions (ID50) or half-maximal inhibitory concentra-
tions (IC50) was calculated to represent the neutralizing activity.
2.5. Monoclonal antibody preparation
One week after the final immunization, splenic cells from mice
immunized with CRM197-A-4E10 were harvested and fused with sp2/0
myeloma cells by PEG2000. The fused cells were seeded into 96-well
plates containing 200 μL of RPMI-1640 medium supplemented with
20% fetal calf serum and hypoxanthine/aminopterin/ thymidine (HAT)
for 1 week. The medium was replenished with fresh medium without
HAT. The supernatants of the hybridomas were screened by ELISA to
identify a specific reaction with the MPER peptide. Positive hybridoma
cells were sub-cloned three times to obtain monoclonal antibodies.
These cell lines were then injected into F1 mice to obtain ascites fluids.
IgG isotype antibodies were precipitated with ammonium sulphate
followed by protein A; IgM subtype antibodies were purified subse-
quently using phenyl and hydroxyapatite.
2.6. Alanine scanning mutagenesis
For the construction of alanine-replaced mutant protein, to elim-
inate the potential influence raised by CRM197-A antibodies in epitope
Fig. 3. Characterization of five CRMA197-A-4E10 elicited monoclonal antibodies. (A) Sequence alignment. (B) ELISA analyses of reacting with the gp41 extracellular
domain protein produced by HEK293FT cells. gp41 proteins were coated into the wells of a 96-well plate (100 ng/well) and monoclonal antibodies were 5-fold
serially diluted from 10 μg/mL. 4E10 was used as a positive control and a V3-specific antibody (3A7, screened in-house) as a negative control. (C) Neutralizing
activity. The values shown are the IC50. IC50< 100 μg/mL are in bold. IC50> 100 μg/mL indicate that the neutralization was lower than 50% at an antibody
concentration of 100 μg/mL.
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mapping, CTB was used as the otherwise scaffold to fuse 4E10 epitope.
The alanine mutants were introduced to the 4E10 epitope in CTB-4E10
construct using the QuikChange site-directed mutagenesis system
(Agilent, Stratagene) and confirmed by DNA sequencing. Then, the
expression and purification process were conducted same as the above-
mentioned.
2.7. Molecular modeling and molecular docking
A structural model of the mAb 18C8-2 variable region (as a 4E10-
like representative) was built by the homology module of Discovery
Studio 2016 software (Accelrys, San Diego, CA). Briefly, the variable
sequences (VH and VL) of 18C8-2 were blast-searched separately for the
modeling template having the highest sequence identity with the target
sequence. The amino acid sequences of the VH and VL regions of 18C8-
2 were inputted into the software and loop grafting and side-chain
modeling were chosen for the calculations. The obtained model was
further refined by minimizing the energy approach incorporated into
the DS software. Subsequently, we docked the 18C8-2 Fab model onto
the crystal structure of MPER (PDB no. 1TZG) using the Zdock module
with prior knowledge of the key residues involved in the interaction of
18C8-2 and MPER. The top-scoring predictions were refined using the
RDOCK suite. All refined predictions were re-ranked and the best or-
ientation was selected as the final complex model. All maps rendering
the complex structures in this study were prepared by the program
PyMol (http://www.pymol.org/).
3. Results
3.1. Construction and characterization of fusion proteins
To enhance MPER immunogenicity, we fused HIV-1MPER neu-
tralizing epitopes to the C-terminus of CRM197-A, an intramolecular
adjuvant, using a GGGGSGGGGSGGGGS linker, and generated two
Fig. 4. Alanine scanning mutagenesis was used to map the binding sites of antibodies. (A) ELISA analysis of antibody-binding residues. The epitope (LWNWFNI-
TNWL) was fused onto Cholera Toxin B-Subunit (CTB) vector and single mutation fusion proteins were expressed and purified. Mutated proteins were coated into the
wells of a 96-well plate at 100 ng/well, and all the antibodies were diluted at 4 μg/mL to react with the mutated proteins. The binding results are shown as OD values.
Wild-type (WT) is the fused protein without any mutation (control). (B) The binding sites of antibodies on the MPER peptide. These sites were obtained from the
alanine scanning mutagenesis assay. The mutations that significantly reduce antibody binding is indicated by different colors.
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fusion proteins, designated CRM197-A-2F5 and CRM197-A-4E10
(Fig. 1A, 1B). The fusion proteins expressed as inclusion bodies in E.
coli. Following purification, the fusion proteins were observed to mi-
grate at ˜30 kDa on 12% reduced SDS-PAGE (Fig. 1C). Immunoblotting
with 2F5 and 4E10 antibodies showed the positive reactivity and con-
firmed the expression of the fusion proteins (Fig. 1C), with CRM197-A
protein used as a negative control. Using ELISA, we found that the
CRM197-A-2F5 and CRM197-A-4E10 proteins had good reactivity with
the human 2F5 and 4E10 antibodies, respectively. Overall, these results
indicated that the 2F5 and 4E10 epitopes, fused with CRM197-A,
showed faithful antigenicity (Fig. 1D).
3.2. Immunization and immunogenicity analysis
BALB/C mice were immunized with fusion proteins via a prime-
boost immunization scheme. To evaluate the immunogenicity of the
fusion proteins, we tested the antisera taken from mice at 8 weeks after
the first immunization using ELISA. Both CRM197-A-2F5 and CRM197-
A-4E10 induced strong antibody titers (˜106), indicating good im-
munogenicity of the fusion proteins in BALB/c mice (Fig. 2A). Next, to
further assess the specific anti-MPER reactivity of the antisera, we ex-
amined whether the antisera could react with the whole gp41 extra-
cellular domain protein (containing MPER) produced in HEK293FT
cells. We found that the antisera from all mice exhibited the specific
reactivity with the gp41 extracellular domain protein at a 100-fold
dilution (Fig. 2B). These results indicated that both CRM197-A-2F5 and
CRM197-A-4E10 proteins elicited HIV epitope-specific antibody re-
sponses in BALB/c mice.
Subsequently, we used TZM-b1 neutralization assay to determine
the neutralizing activity of the antisera against four HIV-1 viral strains:
HIVNL4-3 (clade B), HIV89.6 (clade B), HIVMJ4 (clade C) and HIV94UG114
(clade D). The neutralizing ID50 value showed that the antisera from
CRM197-A-4E10 could neutralize HIVNL4-3, HIV89.6, and HIV94UG114,
whereas antisera from CRM197-A-2F5 only neutralized HIVNL4-3 in
Fig. 2C. The pre-immune serum did not have any detectable neu-
tralizing activity against the same virus. Thus, the antisera from
CRM197-A-4E10 had broader neutralizing activity than did CRM197-A-
2F5. There was no neutralizing activity against HIVMJ4 from either
antiserum. These results suggest that the CRM197-A-4E10 fusion pro-
teins can induce cross-clade neutralizing antibodies against the HIV
MPER epitope.
3.3. Generation and characterization of monoclonal antibodies
To further evaluate the specific epitope responses after immuniza-
tion with the fusion proteins, hybridomas generated from a CRM197-A-
4E10-immunized mouse with the highest cross-clade neutralizing ac-
tivity were screened by ELISA using the MPER peptide as a probe. We
Fig. 5. Cartoon model of the 18C8-2 Fab-MPER complex. (A) Overall model of the 18C8-2 Fab-MPER complex. (B) The interface of the 18C8-2 Fab–MPER complex.
The green dotted line indicates a hydrogen bond and the purple dotted line represents a Pi (π) bond. L (wheat) and H (yellow) represent the light and heavy chains of
Fab. MPER is light pink. (C) Comparison of 18C8-2 with 4E10 in the recognition of the MPER. (D) Binding epitopes in MPER recognized by 18C8-2 and 4E10. The
4E10 epitope is red whereas the 18C8-2 epitope contains both red and yellow areas.
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acquired a total of 5 monoclonal antibodies: 4 IgM and 1 IgG subtypes.
Their sequence alignment showed in Fig. 3A. Obviously, the length of
complementarity determining region 3 (CDR3) in heavy chain is shorter
than that of human mAb 4E10. We tested the binding activity of the
antibodies to the gp41 extracellular domain protein containing the
MPER and compared the binding against that measured with 4E10. We
found that 21A1-4 had better reactivity than 4E10; 18C8-2 had similar
reactivity; and13B8, 17D6 and 25G8 had weaker reactivity (Fig. 3B).
Next, we used a native virion-based neutralization assay to determine
the neutralizing activity of these antibodies. Notably, the IgG-type an-
tibody (18C8-2) showed cross-clade neutralizing activity, whereas the
IgM antibodies (17D6 and 25G8) weakly neutralized the HIV89.6 strain
(Fig. 3C). The sequence alignment of 4E10 epitope in four HIV-1 viruses
showed that N671 and D674 of HIV89.6 strain is different from that of
other three viruses, indicating two crucial neutralization sites for 17D6
and 25G8 (Supplementary Fig. S1). The other antibodies (13B8 and
21A1-4) had binding activity with MPER epitope but no neutralizing
activity. These results suggested the CRM197-A-4E10 fusion protein as
a potential and effective immunogen to elicit neutralizing antibodies.
3.4. Alanine scanning mutagenesis to analyze key recognition sites
To further define the key amino acid residues required for antibody
recognition, we conducted alanine scanning mutagenesis of the 4E10
epitope. In ELISA analysis, we found the monoclonal antibodies had
weak reactivity with the CRM197-A vector protein (Supplementary Fig.
S2), suggested that the antibodies epitopes involve several amino acid
residues located in the CRM197-A. To avoid the interference of
CRM197-A vector on epitope mapping, we fused the 4E10 epitope to
another Cholera Toxin B-Subunit (CTB) vector [40–42], and measured
the reactivity of the resultant proteins to the 5 mAbs using ELISA
(Fig. 4A). In the reactivity profile, we found that residue T676 is critical
for the binding of all antibodies to MPER. Residues N671, W672, F673,
N674, I675, T676 and L679 are also involved in the binding of mAb
4E10 to MPER, consistent with a previous report [16]. Mutations in
residues L669 and W678 also affected the binding of 18C8-2 (Fig. 4A).
Overall, mAb 18C8-2 shared a similar reaction profile to that of mAb
4E10, but were remarkably different to those of clade-specific and non-
neutralizing antibodies. These findings suggest that mAb 18C8-2 re-
cognize an epitope overlapping with the 4E10 epitope, as shown in the
MPER structure (Fig. 4B, Supplementary Table 1).
3.5. Structural modeling of 18C8-2 Fab in complex with the MPER peptide
To further map the epitope defined by 4E10-like antibodies, we
chose 18C8-2 as a representative antibody to molecularly model the
antibody:MPER complex; 18C8-2 was selected as it had the best neu-
tralizing potency and a broad antiviral activity. The initial structural
model of the 18C8-2 Fab was generated using the Modeler module in
the Discovery Studio (DS) software (see Methods). In the complex
model, the 18C8-2 antibody mainly recognized the MPER peptide by Pi
(π) bonding and hydrogen bonding (Fig. 5A, Supplementary Table 2).
Specifically, the molecular interaction between the 18C8-2 Fab frag-
ment and the MPER was mediated by intermolecular π bonds between
the D31L, W105L, Y116L, F114L, H40H, W55H side-chains of the 18C8-
2 heavy chains, and the F673, N677, W680, I675, L679 side-chains of
MPER. Hydrogen bonds were formed by the D31L, K108L, Y116L, F114L,
G108H side-chains of 18C8-2 and the N677, T676, W672, L679 side-
chains of MPER, respectively (Fig. 5B). Compared with 4E10, 18C8-
2 has a different binding orientation. The model also indicates that
18C8-2 binding covers more amino acid residues than does that of 4E10
(Fig. 5C, D).
4. Discussion
Although the current anti-retroviral therapy (ART) has turned HIV-1
infection from a lethal disease to a chronic and manageable one, the
development of HIV-1 vaccine is still urgent and full of challenging. The
RV144 vaccine was the first vaccine to show 31.2% protection from
HIV-1 infection over a period of 42 months, which encouraged the
development of HIV-1 vaccine [43]. In recent years, abundant struc-
tures of bNAbs isolated from the HIV-1 infected individuals have been
solved through x-ray crystallography and cryo-EM and provided valu-
able structural information for the immunogen design. Recently, Xu
et al. exploited a iterative structure-based optimization to design FP-
bearing immunogens, demonstrating the elicitation of FP specific neu-
tralizing antibodies [44]. Thus, the epitope-based approach to generate
effective bNAbs seems to be promising.
In addition to FP epitope, the linear and conserved MPER is the
other major target for immunogen design [45]. The MPER is involved in
the virus-infecting process and may be an ideal target for HIV-1 vaccine
development. Despite many efforts, only few MPER-based immunogens
showed the antibody elicitation with low potency and limited breadth.
Ofek and colleagues previously outlined the utility of scaffolding pro-
teins to display target epitopes for the elicitation of structure-specific
antibodies [24]. In order to improve the MPER-based vaccine design,
more aspects should be considered. Others groups have also shown that
the immune system tends to recognize flexible regions in a epitope-
display scaffold [46]. In this study, we utilized CRM197-A as a vector to
display the 2F5 and 4E10 epitopes, joined at the C-terminus of
CRM197-A by a flexible (GGGGS)3 linker, which allowed epitope-pre-
ferred folding. The purified fusion proteins, CRM197-A-2F5 and
CRM197-A-4E10, showed good reactivity with the mAb 2F5 and 4E10
in ELISA analysis. In immunized BALB/C mice, the immune serum had
an antibody titer of ˜106, and could bind to the MPER on the whole
gp41 extracellular domain protein produced in 293FT cells. We found
that the fusion proteins also elicited polyclonal serum capable of neu-
tralizing different HIV-1 clades. Serum from immunization with the
4E10 fusion protein offered better neutralization than that from 2F5,
possibly due to their different epitope on the MPER. Thus, exploitation
on more available broad neutralization epitopes is of importance to
epitope-based vaccine design.
Five monoclonal antibodies were screened via ELISA using the
MPER peptide as a probe. Most of the antibodies were IgM subtype,
with only one IgG antibody. We found that all of the IgM antibodies
reacted better with the MPER peptide than did the IgG antibody (data
not shown), whereas only the IgG-subtype antibody 18C8-2 showed
cross-clade neutralization against the HIV-1 viruses. Among the anti-
bodies, they bound to similar sites as 4E10, whereas 18C8-2 had a
neutralization potency lower than that of 4E10 [17]. The 13B8 and
21A1-4 antibody was unable to neutralize the HIV-1 virus, even though
it recognized the sites important for 4E10 binding, suggesting that other
residues may be necessary for antibody neutralization. There may be
other reasons for the weaker neutralizing ability of the antibodies: 1)
Because all of the antibodies are from mice, they have a shorter CDRH3
(9 aa) of the heavy chain as compared with human antibodies [47]. 2)
These antibodies don’t react with the part of the membrane involved in
antibody recognition and neutralization. 3) Others have shown that the
longer CDRH3 enhances the neutralization activity via additional in-
teractions with the viral lipid membrane rather than exclusively
binding to the epitopes [48–50]. Besides, we found that 18C8-2 anti-
body mainly interacts with MPER through light chain in the structure
model, whereas heavy chain dominates the epitope recognizing in
4E10, 2F5 and 10E8 structures (Supplementary Table 2). It may also
explain the lower neutralizing activity of 18C8-2 than that of 4E10.
In summary, numerous studies have used MPER transplantation
onto surface loops of various protein scaffolds to elicit bNAbs
[23,24,51–54]. In each case, the MPER fusion proteins induced anti-
bodies that could bind to the MPER epitopes, with several also eliciting
weak neutralizing activities. However, none of these previous studies
have been able to elicit 4E10-like monoclonal antibodies that not only
bind to the 4E10 epitope but can also neutralize the HIV-1 virus. Thus,
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our results provide important insight for an MPER-based HIV-1 vaccine
design, and offer evidence to support the use of MPER as a promising
HIV-1 immunogen candidate. Furthermore, an optimization on im-
munization schemes for CRM197-A-MPER proteins may benefit for the
elicitation of neutralizing antibodies with more potent activity and
wider breadth. Moreover, multiple tandem epitope repeats, con-
servative epitope sequence and polyvalent vaccination strategies could
be taken into consideration aiming to produce considerate titer of HIV-
1 bNAb.
Conflict of interest
The authors declare no conflicts of interest.
Acknowledgments
The work was supported by National Natural Science Foundation of
China (Grant no. 81671645, 81371818) and Chinese Scholarship
Council (Grant No. 201706315049).
Appendix A. Supplementary data
Supplementary material related to this article can be found, in the
online version, at doi:https://doi.org/10.1016/j.imlet.2019.07.004.
References
[1] W.C. Koff, HIV vaccine development: challenges and opportunities towards solving
the HIV vaccine-neutralizing antibody problem, Vaccine 30 (2012) 4310–4315.
[2] H.X. Liao, M.C. Levesque, A. Nagel, A. Dixon, R. Zhang, E. Walter, et al., High-
throughput isolation of immunoglobulin genes from single human B cells and ex-
pression as monoclonal antibodies, J Virol Methods 158 (2009) 171–179.
[3] J.F. Scheid, H. Mouquet, N. Feldhahn, B.D. Walker, F. Pereyra, E. Cutrell, et al., A
method for identification of HIV gp140 binding memory B cells in human blood, J
Immunol Methods 343 (2009) 65–67.
[4] T. Tiller, E. Meffre, S. Yurasov, M. Tsuiji, M.C. Nussenzweig, H. Wardemann,
Efficient generation of monoclonal antibodies from single human B cells by single
cell RT-PCR and expression vector cloning, J Immunol Methods 329 (2008)
112–124.
[5] L. Scharf, J.F. Scheid, J.H. Lee, A.P. West Jr., C. Chen, H. Gao, et al., Antibody
8ANC195 reveals a site of broad vulnerability on the HIV-1 envelope spike, Cell Rep
7 (2014) 785–795.
[6] J.F. Scheid, H. Mouquet, B. Ueberheide, R. Diskin, F. Klein, T.Y. Oliveira, et al.,
Sequence and structural convergence of broad and potent HIV antibodies that
mimic CD4 binding, Science 333 (2011) 1633–1637.
[7] Y. Li, S. O’Dell, L.M. Walker, X. Wu, J. Guenaga, Y. Feng, et al., Mechanism of
neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01, J
Virol 85 (2011) 8954–8967.
[8] J. Gorman, C. Soto, M.M. Yang, T.M. Davenport, M. Guttman, R.T. Bailer, et al.,
Structures of HIV-1 Env V1V2 with broadly neutralizing antibodies reveal com-
monalities that enable vaccine design, Nat Struct Mol Biol 23 (2016) 81–90.
[9] J.S. McLellan, M. Pancera, C. Carrico, J. Gorman, J.P. Julien, R. Khayat, et al.,
Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9,
Nature 480 (2011) 336–343.
[10] J.M. Rini, R.L. Stanfield, E.A. Stura, P.A. Salinas, A.T. Profy, I.A. Wilson, Crystal
structure of a human immunodeficiency virus type 1 neutralizing antibody, 50.1, in
complex with its V3 loop peptide antigen, Proc Natl Acad Sci U S A 90 (1993)
6325–6329.
[11] S. Zolla-Pazner, X.P. Kong, X. Jiang, T. Cardozo, A. Nadas, S. Cohen, et al., Cross-
clade HIV-1 neutralizing antibodies induced with V3-scaffold protein immunogens
following priming with gp120 DNA, J Virol 85 (2011) 9887–9898.
[12] M. Pancera, S. Majeed, Y.E. Ban, L. Chen, C.C. Huang, L. Kong, et al., Structure of
HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture
and basis of conformational mobility, Proc Natl Acad Sci U S A 107 (2010)
1166–1171.
[13] R. Kong, K. Xu, T. Zhou, P. Acharya, T. Lemmin, K. Liu, et al., Fusion peptide of HIV-
1 as a site of vulnerability to neutralizing antibody, Science 352 (2016) 828–833.
[14] M.J. van Gils, T.L. van den Kerkhof, G. Ozorowski, C.A. Cottrell, D. Sok,
M. Pauthner, et al., An HIV-1 antibody from an elite neutralizer implicates the
fusion peptide as a site of vulnerability, Nat Microbiol 2 (2016) 16199.
[15] R.M. Cardoso, F.M. Brunel, S. Ferguson, M. Zwick, D.R. Burton, P.E. Dawson, et al.,
Structural basis of enhanced binding of extended and helically constrained peptide
epitopes of the broadly neutralizing HIV-1 antibody 4E10, J Mol Biol 365 (2007)
1533–1544.
[16] R.M. Cardoso, M.B. Zwick, R.L. Stanfield, R. Kunert, J.M. Binley, H. Katinger, et al.,
Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a
highly conserved fusion-associated motif in gp41, Immunity 22 (2005) 163–173.
[17] J. Huang, G. Ofek, L. Laub, M.K. Louder, N.A. Doria-Rose, N.S. Longo, et al., Broad
and potent neutralization of HIV-1 by a gp41-specific human antibody, Nature 491
(2012) 406–412.
[18] H. Liu, X. Su, L. Si, L. Lu, S. Jiang, The development of HIV vaccines targeting gp41
membrane-proximal external region (MPER): challenges and prospects, Protein Cell
(2018), https://doi.org/10.1007/s13238-018-0534-7.
[19] G. Frey, H. Peng, S. Rits-Volloch, M. Morelli, Y. Cheng, B. Chen, A fusion-inter-
mediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies, Proc Natl
Acad Sci U S A 105 (2008) 3739–3744.
[20] J.M. Binley, C.S. Cayanan, C. Wiley, N. Schulke, W.C. Olson, D.R. Burton, Redox-
Triggered Infection by Disulfide-Shackled Human Immunodeficiency Virus Type 1
Pseudovirions, Journal of Virology 77 (2003) 5678–5684.
[21] A.S. Dimitrov, A. Jacobs, C.M. Finnegan, G. Stiegler, H. Katinger, R. Blumenthal,
Exposure of the membrane-proximal external region of HIV-1 gp41 in the course of
HIV-1 envelope glycoprotein-mediated fusion, Biochemistry 46 (2007) 1398–1401.
[22] M.C. Hanson, W. Abraham, M.P. Crespo, S.H. Chen, H. Liu, G.L. Szeto, et al.,
Liposomal vaccines incorporating molecular adjuvants and intrastructural T-cell
help promote the immunogenicity of HIV membrane-proximal external region
peptides, Vaccine 33 (2015) 861–868.
[23] G. Yi, M. Lapelosa, R. Bradley, T.M. Mariano, D.E. Dietz, S. Hughes, et al., Chimeric
rhinoviruses displaying MPER epitopes elicit anti-HIV neutralizing responses, PLoS
One 8 (2013) e72205.
[24] G. Ofek, F.J. Guenaga, W.R. Schief, J. Skinner, D. Baker, R. Wyatt, et al., Elicitation
of structure-specific antibodies by epitope scaffolds, Proc Natl Acad Sci U S A 107
(2010) 17880–17887.
[25] S.A. Kessans, M.D. Linhart, N. Matoba, T. Mor, Biological and biochemical char-
acterization of HIV-1 Gag/dgp41 virus-like particles expressed in Nicotiana ben-
thamiana, Plant Biotechnol J 11 (2013) 681–690.
[26] J. Guenaga, P. Dosenovic, G. Ofek, D. Baker, W.R. Schief, P.D. Kwong, et al.,
Heterologous epitope-scaffold prime:boosting immuno-focuses B cell responses to
the HIV-1 gp41 2F5 neutralization determinant, PLoS One 6 (2011) e16074.
[27] G.Y. Ishioka, A.G. Lamont, D. Thomson, N. Bulbow, F.C. Gaeta, A. Sette, et al., MHC
interaction and T cell recognition of carbohydrates and glycopeptides, J Immunol
148 (1992) 2446–2451.
[28] N. Orr, J.E. Galen, M.M. Levine, Expression and immunogenicity of a mutant
diphtheria toxin molecule, CRM(197), and its fragments in Salmonella typhi vac-
cine strain CVD 908-htrA, Infect Immun 67 (1999) 4290–4294.
[29] P. Cresswell, Assembly, transport, and function of MHC class II molecules, Annu
Rev Immunol 12 (1994) 259–293.
[30] C.L. Trotter, N.J. Andrews, E.B. Kaczmarski, E. Miller, M.E. Ramsay, Effectiveness of
meningococcal serogroup C conjugate vaccine 4 years after introduction, The
Lancet 364 (2004) 365–367.
[31] M.D. Snape, K.P. Perrett, K.J. Ford, T.M. John, D. Pace, L.M. Yu, et al.,
Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a
randomized controlled trial, JAMA 299 (2008) 173–184.
[32] B.G. Van Ness, J.B. Howard, J.W. Bodley, ADP-ribosylation of elongation factor 2 by
diphtheria toxin. NMR spectra and proposed structures of ribosyl-diphthamide and
its hydrolysis products, J Biol Chem 255 (1980) 10710–10716.
[33] R. Drazin, J. Kandel, R.J. Collier, Structure and activity of diphtheria toxin. II.
Attack by trypsin at a specific site within the intact toxin molecule, J Biol Chem 246
(1971) 1504–1510.
[34] D. Wang, Z. Li, J. Xiao, J. Wang, L. Zhang, Y. Liu, et al., Identification of Broad-
Genotype HPV L2 Neutralization Site for Pan-HPV Vaccine Development by a Cross-
Neutralizing Antibody, PLoS One 10 (2015) e0123944.
[35] K. Wang, L. Zhou, X. Zhang, C. Song, T. Chen, J. Li, et al., Hepatitis E vaccine
candidate harboring a non-particulate immunogen of E2 fused with CRM197
fragment A, Antiviral Res 164 (2019) 154–161.
[36] W. Shi, J. Bohon, D.P. Han, H. Habte, Y. Qin, M.W. Cho, et al., Structural char-
acterization of HIV gp41 with the membrane-proximal external region, J Biol Chem
285 (2010) 24290–24298.
[37] W. Hou, C. Fang, J. Liu, H. Yu, J. Qi, Z. Zhang, et al., Molecular insights into the
inhibition of HIV-1 infection using a CD4 domain-1-specific monoclonal antibody,
Antiviral Res 122 (2015) 101–111.
[38] Y. Li, K. Svehla, N.L. Mathy, G. Voss, J.R. Mascola, R. Wyatt, Characterization of
antibody responses elicited by human immunodeficiency virus type 1 primary
isolate trimeric and monomeric envelope glycoproteins in selected adjuvants, J
Virol 80 (2006) 1414–1426.
[39] Y. Shu, S. Winfrey, Z.Y. Yang, L. Xu, S.S. Rao, I. Srivastava, et al., Efficient protein
boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1
vaccine constructs, Vaccine 25 (2007) 1398–1408.
[40] M.T. Dertzbaugh, D.L. Peterson, F.L. Macrina, Cholera toxin B-subunit gene fusion:
structural and functional analysis of the chimeric protein, Infect Immun 58 (1990)
70–79.
[41] E.A. Merritt, P. Kuhn, S. Sarfaty, J.L. Erbe, R.K. Holmes, W.G. Hol, The 1.25 A
resolution refinement of the cholera toxin B-pentamer: evidence of peptide back-
bone strain at the receptor-binding site, J Mol Biol 282 (1998) 1043–1059.
[42] M. Totrov, X. Jiang, X.P. Kong, S. Cohen, C. Krachmarov, A. Salomon, et al.,
Structure-guided design and immunological characterization of immunogens pre-
senting the HIV-1 gp120 V3 loop on a CTB scaffold, Virology 405 (2010) 513–523.
[43] J.T. Safrit, P.E. Fast, L. Gieber, H. Kuipers, H.J. Dean, W.C. Koff, Status of vaccine
research and development of vaccines for HIV-1, Vaccine 34 (2016) 2921–2925.
[44] K. Xu, P. Acharya, R. Kong, C. Cheng, G.Y. Chuang, K. Liu, et al., Epitope-based
vaccine design yields fusion peptide-directed antibodies that neutralize diverse
strains of HIV-1, Nat Med 24 (2018) 857–867.
[45] M.A. Checkley, B.G. Luttge, E.O. Freed, HIV-1 envelope glycoprotein biosynthesis,
trafficking, and incorporation, J Mol Biol 410 (2011) 582–608.
Z. Zhang, et al. Immunology Letters 213 (2019) 30–38
37
[46] V. Manivel, N.C. Sahoo, D.M. Salunke, K.V. Rao, Maturation of an antibody re-
sponse is governed by modulations in flexibility of the antigen-combining site,
Immunity 13 (2000) 611–620.
[47] M. Zemlin, M. Klinger, J. Link, C. Zemlin, K. Bauer, J.A. Engler, et al., Expressed
murine and human CDR-H3 intervals of equal length exhibit distinct repertoires
that differ in their amino acid composition and predicted range of structures, J Mol
Biol 334 (2003) 733–749.
[48] C. Grundner, T. Mirzabekov, J. Sodroski, R. Wyatt, Solid-phase proteoliposomes
containing human immunodeficiency virus envelope glycoproteins, J Virol 76
(2002) 3511–3521.
[49] K. Lacek, R.A. Urbanowicz, F. Troise, C. De Lorenzo, V. Severino, A. Di Maro, et al.,
Dramatic potentiation of the antiviral activity of HIV antibodies by cholesterol
conjugation, J Biol Chem 289 (2014) 35015–35028.
[50] J. Chen, G. Frey, H. Peng, S. Rits-Volloch, J. Garrity, M.S. Seaman, et al.,
Mechanism of HIV-1 neutralization by antibodies targeting a membrane-proximal
region of gp41, J Virol 88 (2014) 1249–1258.
[51] S. Phogat, K. Svehla, M. Tang, A. Spadaccini, J. Muller, J. Mascola, et al., Analysis of
the human immunodeficiency virus type 1 gp41 membrane proximal external re-
gion arrayed on hepatitis B surface antigen particles, Virology 373 (2008) 72–84.
[52] M. Law, R.M. Cardoso, I.A. Wilson, D.R. Burton, Antigenic and immunogenic study
of membrane-proximal external region-grafted gp120 antigens by a DNA prime-
protein boost immunization strategy, J Virol 81 (2007) 4272–4285.
[53] Y. Zhai, Z. Zhong, M. Zariffard, G.T. Spear, L. Qiao, Bovine papillomavirus-like
particles presenting conserved epitopes from membrane-proximal external region of
HIV-1 gp41 induced mucosal and systemic antibodies, Vaccine 31 (2013)
5422–5429.
[54] Y. Yu, L. Fu, Y. Shi, S. Guan, L. Yang, X. Gong, et al., Elicitation of HIV-1 neu-
tralizing antibodies by presentation of 4E10 and 10E8 epitopes on Norovirus P
particles, Immunol Lett 168 (2015) 271–278.
Z. Zhang, et al. Immunology Letters 213 (2019) 30–38
38
